This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mintz, M. Search for Related Content PubMed Articles by Mintz, M. Social Bookmarking                         What's this?

Carnitine in Human Immunodeficiency Virus Type 1 Infection/Acquired Immune Deficiency Syndrome

University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School at Camden, Division of Pediatric Neurology, Cooper Hospital/ University Medical Center, Camden, NJ

There is an increasing body of evidence that subgroups of patients infected with human immunodeficiency virus type 1 possess carnitine deficiency. Secondary carnitine deficiencies in these individuals may result from nutritional deficiencies, gastrointestinal disturbances, renal losses, or shifts in metabolic pathways. However, tissue depletion precipitated by drug toxicities, particularly zidovudine, is a major etiology and concern. Carnitine deficiency may impact on energy and lipid metabolism, causing mitochondrial and immune dysfunction. There are convincing laboratory data showing the in vitro ameliorative effects of L-carnitine supplementation on zidovudine-induced myopathies and lymphocyte function. Studies measuring the impact of L-carnitine supplementation on clinical characteristics are ongoing. (J Child Neurol 1995; 10(Suppl):2540-2544).

Journal of Child Neurology, Vol. 10, No. 2 suppl, 2S40-2S44 (1995)
DOI: 10.1177/088307389501000206


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?